Concepts (328)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 77 | 2024 | 6291 | 6.360 |
Why?
|
Air Pollution, Indoor | 25 | 2024 | 931 | 3.540 |
Why?
|
Bronchopulmonary Dysplasia | 6 | 2024 | 329 | 3.410 |
Why?
|
Environmental Exposure | 28 | 2024 | 4543 | 2.170 |
Why?
|
Air Pollution | 8 | 2024 | 2374 | 2.030 |
Why?
|
Spirometry | 10 | 2024 | 929 | 1.800 |
Why?
|
Schools | 25 | 2024 | 1498 | 1.640 |
Why?
|
Allergens | 19 | 2023 | 1443 | 1.570 |
Why?
|
Radon | 2 | 2023 | 91 | 1.510 |
Why?
|
Air Pollutants | 8 | 2024 | 2916 | 1.500 |
Why?
|
Particulate Matter | 9 | 2024 | 2617 | 1.480 |
Why?
|
Nitrogen Dioxide | 7 | 2024 | 534 | 1.340 |
Why?
|
Anti-Asthmatic Agents | 7 | 2021 | 577 | 1.250 |
Why?
|
Child | 89 | 2024 | 80917 | 1.120 |
Why?
|
Respiratory Sounds | 4 | 2021 | 702 | 1.050 |
Why?
|
Urban Population | 21 | 2024 | 2046 | 1.000 |
Why?
|
Respiratory Function Tests | 13 | 2023 | 1695 | 0.960 |
Why?
|
Bronchodilator Agents | 9 | 2022 | 518 | 0.900 |
Why?
|
Oscillometry | 1 | 2024 | 151 | 0.890 |
Why?
|
Proxy | 1 | 2024 | 150 | 0.870 |
Why?
|
Forced Expiratory Volume | 10 | 2024 | 1831 | 0.870 |
Why?
|
Smoke | 1 | 2024 | 242 | 0.820 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2023 | 794 | 0.670 |
Why?
|
Ribs | 1 | 2020 | 259 | 0.610 |
Why?
|
Blood Gas Monitoring, Transcutaneous | 1 | 2018 | 34 | 0.610 |
Why?
|
Vital Capacity | 6 | 2024 | 996 | 0.570 |
Why?
|
Oxidants, Photochemical | 1 | 2017 | 77 | 0.570 |
Why?
|
Inhalation Exposure | 1 | 2020 | 432 | 0.570 |
Why?
|
Sleep Apnea Syndromes | 2 | 2024 | 984 | 0.540 |
Why?
|
Technology | 1 | 2019 | 296 | 0.540 |
Why?
|
Precancerous Conditions | 1 | 2023 | 985 | 0.530 |
Why?
|
Diet, Mediterranean | 1 | 2023 | 748 | 0.530 |
Why?
|
Nasal Polyps | 1 | 2021 | 412 | 0.520 |
Why?
|
Lung Diseases | 3 | 2024 | 1944 | 0.470 |
Why?
|
Communicable Disease Control | 1 | 2021 | 857 | 0.460 |
Why?
|
Egg Hypersensitivity | 2 | 2012 | 47 | 0.450 |
Why?
|
Morbidity | 9 | 2023 | 1755 | 0.450 |
Why?
|
Child, Preschool | 33 | 2024 | 42669 | 0.440 |
Why?
|
Asthma, Exercise-Induced | 1 | 2013 | 23 | 0.440 |
Why?
|
Respiratory Hypersensitivity | 1 | 2015 | 272 | 0.440 |
Why?
|
Dermatitis, Atopic | 3 | 2024 | 737 | 0.440 |
Why?
|
Humans | 114 | 2024 | 768166 | 0.440 |
Why?
|
Adrenal Cortex Hormones | 8 | 2021 | 1886 | 0.440 |
Why?
|
Self Report | 1 | 2024 | 3773 | 0.420 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 2014 | 216 | 0.410 |
Why?
|
Sinusitis | 1 | 2021 | 997 | 0.400 |
Why?
|
Parents | 3 | 2024 | 3595 | 0.400 |
Why?
|
Cockroaches | 4 | 2021 | 92 | 0.400 |
Why?
|
Virus Diseases | 2 | 2017 | 724 | 0.390 |
Why?
|
Circadian Rhythm | 1 | 2023 | 2593 | 0.380 |
Why?
|
Cities | 5 | 2024 | 543 | 0.360 |
Why?
|
Nut Hypersensitivity | 1 | 2010 | 33 | 0.360 |
Why?
|
Bronchiolitis | 1 | 2017 | 492 | 0.350 |
Why?
|
Health Status | 1 | 2023 | 4091 | 0.350 |
Why?
|
Environmental Monitoring | 5 | 2024 | 1469 | 0.330 |
Why?
|
Adolescent | 34 | 2024 | 89169 | 0.330 |
Why?
|
Female | 59 | 2024 | 397192 | 0.330 |
Why?
|
Tobacco Smoke Pollution | 1 | 2015 | 828 | 0.330 |
Why?
|
Male | 58 | 2024 | 364719 | 0.320 |
Why?
|
Biomedical Research | 2 | 2024 | 3463 | 0.310 |
Why?
|
Quality of Life | 4 | 2024 | 13490 | 0.310 |
Why?
|
Monitoring, Physiologic | 1 | 2016 | 1798 | 0.310 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2021 | 1899 | 0.310 |
Why?
|
Desensitization, Immunologic | 2 | 2015 | 558 | 0.300 |
Why?
|
Nitric Oxide | 4 | 2023 | 2146 | 0.290 |
Why?
|
Hematopoiesis, Extramedullary | 1 | 2007 | 53 | 0.290 |
Why?
|
Dust | 6 | 2022 | 488 | 0.290 |
Why?
|
Vehicle Emissions | 2 | 2024 | 651 | 0.280 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1444 | 0.270 |
Why?
|
Leukotriene Antagonists | 2 | 2018 | 124 | 0.270 |
Why?
|
Administration, Inhalation | 6 | 2019 | 1169 | 0.270 |
Why?
|
Mental Health | 1 | 2020 | 3275 | 0.260 |
Why?
|
Hypersensitivity | 4 | 2019 | 1172 | 0.260 |
Why?
|
Lung | 7 | 2024 | 10099 | 0.250 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3929 | 0.240 |
Why?
|
Cystic Fibrosis | 2 | 2024 | 1294 | 0.230 |
Why?
|
Housing | 7 | 2022 | 683 | 0.220 |
Why?
|
Solar Activity | 1 | 2023 | 44 | 0.220 |
Why?
|
Volatile Organic Compounds | 1 | 2024 | 86 | 0.220 |
Why?
|
Infant, Newborn | 9 | 2024 | 26422 | 0.220 |
Why?
|
Poverty Areas | 2 | 2023 | 268 | 0.210 |
Why?
|
Seasons | 4 | 2024 | 1524 | 0.210 |
Why?
|
Histamine H2 Antagonists | 1 | 2024 | 169 | 0.210 |
Why?
|
Exanthema | 1 | 2007 | 503 | 0.210 |
Why?
|
Pyroglyphidae | 3 | 2015 | 92 | 0.200 |
Why?
|
Respiratory Rate | 1 | 2023 | 180 | 0.200 |
Why?
|
Comorbidity | 4 | 2024 | 10590 | 0.200 |
Why?
|
Breath Tests | 3 | 2018 | 300 | 0.200 |
Why?
|
Albuterol | 3 | 2018 | 211 | 0.190 |
Why?
|
Rodent Control | 1 | 2021 | 15 | 0.190 |
Why?
|
Pharmacy | 1 | 2023 | 92 | 0.190 |
Why?
|
Endotoxins | 2 | 2015 | 519 | 0.190 |
Why?
|
Spores, Fungal | 2 | 2019 | 90 | 0.190 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7951 | 0.190 |
Why?
|
Cytomegalovirus Infections | 1 | 2007 | 837 | 0.180 |
Why?
|
Eczema | 2 | 2015 | 245 | 0.180 |
Why?
|
Immunoglobulin E | 6 | 2020 | 1506 | 0.180 |
Why?
|
Ozone | 1 | 2024 | 496 | 0.170 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 4055 | 0.170 |
Why?
|
Socioeconomic Factors | 3 | 2023 | 7852 | 0.170 |
Why?
|
Humidity | 1 | 2021 | 207 | 0.170 |
Why?
|
Delphi Technique | 1 | 2024 | 891 | 0.170 |
Why?
|
Peak Expiratory Flow Rate | 2 | 2018 | 144 | 0.170 |
Why?
|
Cats | 4 | 2017 | 978 | 0.170 |
Why?
|
Fungi | 3 | 2022 | 345 | 0.170 |
Why?
|
Climate Change | 2 | 2024 | 509 | 0.160 |
Why?
|
Snoring | 1 | 2021 | 211 | 0.160 |
Why?
|
DNA Methylation | 1 | 2014 | 4428 | 0.160 |
Why?
|
Proton Pump Inhibitors | 1 | 2024 | 552 | 0.160 |
Why?
|
Infant | 13 | 2024 | 36535 | 0.160 |
Why?
|
Alternaria | 1 | 2019 | 41 | 0.160 |
Why?
|
Prospective Studies | 14 | 2024 | 54926 | 0.160 |
Why?
|
Acute Chest Syndrome | 1 | 2018 | 32 | 0.150 |
Why?
|
Premature Birth | 2 | 2021 | 1829 | 0.150 |
Why?
|
Risk | 3 | 2017 | 9613 | 0.150 |
Why?
|
Hospitals, Pediatric | 2 | 2018 | 1876 | 0.150 |
Why?
|
Antiviral Agents | 1 | 2010 | 3073 | 0.150 |
Why?
|
Convalescence | 1 | 2018 | 107 | 0.150 |
Why?
|
Adolescent Development | 1 | 2021 | 276 | 0.150 |
Why?
|
Pest Control | 1 | 2017 | 29 | 0.140 |
Why?
|
Insect Bites and Stings | 1 | 2017 | 72 | 0.140 |
Why?
|
Skin Tests | 3 | 2017 | 639 | 0.140 |
Why?
|
Insurance Claim Review | 1 | 2021 | 744 | 0.140 |
Why?
|
Maximal Midexpiratory Flow Rate | 2 | 2016 | 75 | 0.140 |
Why?
|
Dogs | 4 | 2017 | 3845 | 0.130 |
Why?
|
Cohort Studies | 8 | 2024 | 41754 | 0.130 |
Why?
|
Medication Adherence | 3 | 2023 | 2187 | 0.130 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2016 | 110 | 0.130 |
Why?
|
Fatigue | 1 | 2023 | 1557 | 0.130 |
Why?
|
Breast Neoplasms | 1 | 2023 | 21206 | 0.130 |
Why?
|
Bronchoconstriction | 1 | 2016 | 141 | 0.130 |
Why?
|
Age Factors | 7 | 2021 | 18412 | 0.130 |
Why?
|
Caregivers | 3 | 2017 | 2302 | 0.120 |
Why?
|
Antibodies, Monoclonal | 2 | 2020 | 9263 | 0.120 |
Why?
|
Pulmonary Medicine | 1 | 2017 | 223 | 0.120 |
Why?
|
Psychology | 1 | 2017 | 353 | 0.120 |
Why?
|
Ibuprofen | 1 | 2016 | 229 | 0.120 |
Why?
|
Severity of Illness Index | 9 | 2021 | 15948 | 0.120 |
Why?
|
Self-Assessment | 1 | 2017 | 400 | 0.120 |
Why?
|
Carbon Monoxide | 1 | 2018 | 560 | 0.120 |
Why?
|
Temperature | 1 | 2021 | 2234 | 0.120 |
Why?
|
Mycoses | 1 | 2017 | 386 | 0.120 |
Why?
|
Practice Guidelines as Topic | 2 | 2016 | 7454 | 0.120 |
Why?
|
Azithromycin | 1 | 2015 | 201 | 0.110 |
Why?
|
Disease Progression | 5 | 2018 | 13671 | 0.110 |
Why?
|
Gonadal Steroid Hormones | 1 | 2018 | 707 | 0.110 |
Why?
|
Exhalation | 1 | 2015 | 185 | 0.110 |
Why?
|
Young Adult | 7 | 2023 | 60066 | 0.110 |
Why?
|
Alcohol-Related Disorders | 1 | 2016 | 243 | 0.110 |
Why?
|
School Health Services | 1 | 2017 | 388 | 0.110 |
Why?
|
Longitudinal Studies | 4 | 2023 | 14783 | 0.110 |
Why?
|
Minority Groups | 1 | 2021 | 1216 | 0.110 |
Why?
|
United States | 16 | 2024 | 73039 | 0.110 |
Why?
|
Massachusetts | 2 | 2024 | 8890 | 0.100 |
Why?
|
Steroids | 1 | 2018 | 938 | 0.100 |
Why?
|
Diagnosis, Differential | 2 | 2018 | 13014 | 0.100 |
Why?
|
Risk Factors | 9 | 2021 | 74944 | 0.100 |
Why?
|
Acetaminophen | 1 | 2016 | 552 | 0.100 |
Why?
|
Adult | 10 | 2023 | 223646 | 0.100 |
Why?
|
Social Class | 1 | 2021 | 2008 | 0.100 |
Why?
|
Mass Screening | 2 | 2019 | 5458 | 0.100 |
Why?
|
Phenotype | 3 | 2021 | 16726 | 0.100 |
Why?
|
Prevalence | 5 | 2021 | 15869 | 0.100 |
Why?
|
Perinatal Care | 1 | 2014 | 245 | 0.100 |
Why?
|
Immunity | 1 | 2017 | 1003 | 0.100 |
Why?
|
Treatment Failure | 1 | 2018 | 2661 | 0.100 |
Why?
|
Soot | 2 | 2024 | 219 | 0.100 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26379 | 0.090 |
Why?
|
Infant, Premature | 1 | 2021 | 2124 | 0.090 |
Why?
|
Counseling | 1 | 2019 | 1554 | 0.090 |
Why?
|
Feeding Behavior | 1 | 2023 | 3205 | 0.090 |
Why?
|
Eggs | 1 | 2012 | 182 | 0.090 |
Why?
|
Drug Resistance | 1 | 2017 | 1599 | 0.090 |
Why?
|
Edema | 1 | 2015 | 765 | 0.090 |
Why?
|
Vulnerable Populations | 1 | 2016 | 718 | 0.090 |
Why?
|
Sex Characteristics | 1 | 2021 | 2650 | 0.090 |
Why?
|
Pain | 2 | 2023 | 5100 | 0.090 |
Why?
|
Societies, Medical | 2 | 2024 | 3968 | 0.090 |
Why?
|
Mitosporic Fungi | 1 | 2009 | 17 | 0.080 |
Why?
|
Occupational Diseases | 1 | 2017 | 1457 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2017 | 1397 | 0.080 |
Why?
|
Animals, Domestic | 1 | 2009 | 56 | 0.080 |
Why?
|
Child Development | 1 | 2021 | 2330 | 0.080 |
Why?
|
Secondary Prevention | 1 | 2015 | 1474 | 0.080 |
Why?
|
Anxiety Disorders | 1 | 2020 | 2748 | 0.080 |
Why?
|
Safety | 1 | 2014 | 1159 | 0.080 |
Why?
|
CpG Islands | 1 | 2014 | 1208 | 0.080 |
Why?
|
Urban Health | 1 | 2011 | 535 | 0.080 |
Why?
|
Dyspnea | 2 | 2014 | 1352 | 0.080 |
Why?
|
Radiography | 1 | 2020 | 6983 | 0.080 |
Why?
|
Sleep | 2 | 2024 | 4819 | 0.080 |
Why?
|
Double-Blind Method | 4 | 2018 | 12465 | 0.080 |
Why?
|
Health Services Accessibility | 2 | 2024 | 5520 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4260 | 0.080 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12077 | 0.080 |
Why?
|
Boston | 4 | 2021 | 9374 | 0.080 |
Why?
|
Perception | 1 | 2015 | 1209 | 0.080 |
Why?
|
Disease Susceptibility | 2 | 2017 | 1793 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 1 | 2018 | 1805 | 0.080 |
Why?
|
RNA Viruses | 1 | 2009 | 112 | 0.070 |
Why?
|
Chronic Disease | 2 | 2021 | 9384 | 0.070 |
Why?
|
Quality of Health Care | 1 | 2023 | 4310 | 0.070 |
Why?
|
Respiratory Tract Infections | 1 | 2015 | 1014 | 0.070 |
Why?
|
Disease Management | 1 | 2018 | 2536 | 0.070 |
Why?
|
Cross-Over Studies | 1 | 2013 | 2107 | 0.070 |
Why?
|
Ganciclovir | 1 | 2007 | 256 | 0.070 |
Why?
|
Pediatrics | 2 | 2024 | 3629 | 0.070 |
Why?
|
Rhinitis | 1 | 2014 | 753 | 0.060 |
Why?
|
Exercise Test | 1 | 2013 | 2186 | 0.060 |
Why?
|
Food Hypersensitivity | 1 | 2013 | 734 | 0.060 |
Why?
|
Anxiety | 1 | 2020 | 4672 | 0.060 |
Why?
|
Quantitative Trait Loci | 1 | 2014 | 2131 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4206 | 0.060 |
Why?
|
Education, Medical, Graduate | 1 | 2017 | 2420 | 0.060 |
Why?
|
Length of Stay | 1 | 2018 | 6498 | 0.060 |
Why?
|
Patient Satisfaction | 1 | 2017 | 3488 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2016 | 3573 | 0.060 |
Why?
|
Sex Factors | 1 | 2018 | 10632 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2014 | 2118 | 0.060 |
Why?
|
Curriculum | 1 | 2017 | 3782 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10399 | 0.050 |
Why?
|
Parabens | 1 | 2024 | 118 | 0.050 |
Why?
|
Students | 4 | 2015 | 1744 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2016 | 4045 | 0.050 |
Why?
|
Attitude to Health | 1 | 2012 | 2025 | 0.050 |
Why?
|
Animals | 11 | 2022 | 169246 | 0.050 |
Why?
|
Mice | 8 | 2022 | 82029 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20227 | 0.050 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1668 | 0.050 |
Why?
|
Promoter Regions, Genetic | 1 | 2014 | 5797 | 0.050 |
Why?
|
Rodenticides | 1 | 2021 | 21 | 0.050 |
Why?
|
Quality Improvement | 1 | 2017 | 3857 | 0.050 |
Why?
|
Stress, Psychological | 1 | 2017 | 4530 | 0.050 |
Why?
|
Clinical Protocols | 2 | 2021 | 1443 | 0.050 |
Why?
|
Infusions, Parenteral | 1 | 2021 | 396 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 30010 | 0.050 |
Why?
|
Inflammation | 2 | 2018 | 10873 | 0.040 |
Why?
|
Phenols | 1 | 2024 | 526 | 0.040 |
Why?
|
Obesity | 2 | 2020 | 13090 | 0.040 |
Why?
|
Cytokinesis | 1 | 2021 | 170 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 3833 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 20760 | 0.040 |
Why?
|
Rats | 2 | 2017 | 23760 | 0.040 |
Why?
|
Mediastinum | 1 | 2021 | 272 | 0.040 |
Why?
|
Health Services | 2 | 2017 | 755 | 0.040 |
Why?
|
Phthalic Acids | 1 | 2024 | 487 | 0.040 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2022 | 453 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 640 | 0.040 |
Why?
|
Sulfur | 1 | 2019 | 158 | 0.040 |
Why?
|
Biomass | 1 | 2019 | 135 | 0.040 |
Why?
|
Geography | 1 | 2021 | 652 | 0.040 |
Why?
|
Air Microbiology | 1 | 2019 | 95 | 0.040 |
Why?
|
Carbon | 1 | 2022 | 673 | 0.040 |
Why?
|
Health Status Disparities | 2 | 2024 | 1885 | 0.040 |
Why?
|
Cough | 1 | 2022 | 598 | 0.040 |
Why?
|
Antigens, Fungal | 1 | 2017 | 69 | 0.040 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2021 | 572 | 0.040 |
Why?
|
Venoms | 1 | 2017 | 94 | 0.040 |
Why?
|
Advisory Committees | 1 | 2021 | 797 | 0.040 |
Why?
|
Algorithms | 1 | 2018 | 14164 | 0.040 |
Why?
|
Polysomnography | 1 | 2024 | 1871 | 0.040 |
Why?
|
Mites | 1 | 2017 | 46 | 0.030 |
Why?
|
Ipratropium | 1 | 2016 | 19 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2015 | 7477 | 0.030 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2022 | 621 | 0.030 |
Why?
|
Population | 1 | 2017 | 141 | 0.030 |
Why?
|
Body Weights and Measures | 1 | 2017 | 208 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2022 | 1183 | 0.030 |
Why?
|
ROC Curve | 2 | 2016 | 3628 | 0.030 |
Why?
|
Treatment Outcome | 5 | 2024 | 65371 | 0.030 |
Why?
|
Growth | 1 | 2018 | 366 | 0.030 |
Why?
|
Particle Size | 1 | 2019 | 1649 | 0.030 |
Why?
|
Environmental Pollutants | 1 | 2024 | 1296 | 0.030 |
Why?
|
Puberty | 1 | 2018 | 501 | 0.030 |
Why?
|
Antigens, Dermatophagoides | 1 | 2015 | 101 | 0.030 |
Why?
|
Cost of Illness | 1 | 2024 | 1951 | 0.030 |
Why?
|
Consensus | 1 | 2024 | 3212 | 0.030 |
Why?
|
Sputum | 1 | 2017 | 517 | 0.030 |
Why?
|
Population Surveillance | 1 | 2024 | 2596 | 0.030 |
Why?
|
Pilot Projects | 2 | 2018 | 8741 | 0.030 |
Why?
|
PubMed | 1 | 2014 | 129 | 0.030 |
Why?
|
Research Design | 2 | 2021 | 6211 | 0.030 |
Why?
|
Recurrence | 2 | 2016 | 8509 | 0.030 |
Why?
|
Antigens, Viral | 1 | 2017 | 995 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2017 | 1587 | 0.030 |
Why?
|
Colony Count, Microbial | 1 | 2013 | 328 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2019 | 939 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 8054 | 0.030 |
Why?
|
Administration, Topical | 1 | 2015 | 703 | 0.030 |
Why?
|
Pregnancy | 1 | 2014 | 30256 | 0.020 |
Why?
|
Antigens, Bacterial | 1 | 2017 | 1150 | 0.020 |
Why?
|
Cyclosporine | 1 | 2015 | 777 | 0.020 |
Why?
|
Gestational Age | 1 | 2021 | 3621 | 0.020 |
Why?
|
Eosinophils | 1 | 2017 | 952 | 0.020 |
Why?
|
Skin Care | 1 | 2012 | 55 | 0.020 |
Why?
|
Sex Distribution | 1 | 2017 | 2278 | 0.020 |
Why?
|
Tacrolimus | 1 | 2015 | 750 | 0.020 |
Why?
|
Body Mass Index | 2 | 2020 | 13053 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3436 | 0.020 |
Why?
|
New England | 1 | 2013 | 1058 | 0.020 |
Why?
|
Eosinophilia | 1 | 2015 | 556 | 0.020 |
Why?
|
Anemia, Sickle Cell | 1 | 2018 | 1065 | 0.020 |
Why?
|
Middle Aged | 4 | 2021 | 223492 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2016 | 39348 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3415 | 0.020 |
Why?
|
Fever | 1 | 2016 | 1614 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2015 | 1063 | 0.020 |
Why?
|
Linear Models | 1 | 2018 | 5884 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4860 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2021 | 81762 | 0.020 |
Why?
|
Risk Assessment | 2 | 2021 | 24315 | 0.020 |
Why?
|
Hospitals | 1 | 2020 | 3886 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10760 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6526 | 0.020 |
Why?
|
Poverty | 1 | 2017 | 2720 | 0.020 |
Why?
|
Inpatients | 1 | 2016 | 2566 | 0.010 |
Why?
|
Registries | 1 | 2021 | 8375 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2018 | 5349 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5536 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10101 | 0.010 |
Why?
|
Critical Care | 1 | 2016 | 2715 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3231 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 8080 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21538 | 0.010 |
Why?
|
Aged | 2 | 2021 | 171504 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 59629 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 22291 | 0.010 |
Why?
|
Hospitalization | 1 | 2013 | 10840 | 0.010 |
Why?
|
Concepts
(328)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(82)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_